TTM2-TAME Trial



Can’t sign in or forgot your password?

Enter your email address and we will send you password reset instructions.

Enter your email address


      Nevermind, send me back to the log in screen
   

Site User?

You don't have an email address so you need to contact the PLUS Project Manager or CRA to have your password reset.

 

About the TTM2 Study

The TTM2 trial is a phase III, multi-centre, randomized, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to investigate whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C. More information »

About the TAME Study

The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN). More information »

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.